Markets:

Overview

News

Currencies

International

Treasuries

UroGen Pharma Ltd. - Ordinary Shares (NQ:URGN)

21.94 -0.19 (-0.86%)

Streaming Delayed Price Updated: 12:49 PM EST, Jan 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about UroGen Pharma Ltd. - Ordinary Shares

< Previous 1 2 3 4 Next >

Billionaire Family Office Dumps All of Its UroGen Stock Amid 100% Rally ↗

December 26, 2025

A full exit after a monster rally says less about the company’s science and more about how disciplined funds lock in wins when portfolio math starts to matter.

Via The Motley Fool

Topics Death Regulatory Compliance

UroGen (URGN) Q3 2025 Earnings Call Transcript ↗

November 06, 2025

UroGen (URGN) Q3 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

UROGEN PHARMA LTD (NASDAQ:URGN) Reports Q3 2025 Earnings: Revenue Misses, Loss Per Share Beats ↗

November 06, 2025

UroGen Q3 2025 results show a revenue miss but a narrower-than-expected loss. The biopharma highlighted strong pipeline progress and the ongoing launch of its new product, ZUSDURI.

Via Chartmill

Earnings Scheduled For November 6, 2025 ↗

November 06, 2025

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

October 24, 2025

Via Benzinga

Earnings Scheduled For August 7, 2025 ↗

August 07, 2025

Via Benzinga

Earnings Scheduled For May 12, 2025 ↗

May 12, 2025

Via Benzinga

A Look at UroGen Pharma's Upcoming Earnings Report ↗

May 09, 2025

Via Benzinga

UroGen (URGN) Q2 Revenue Rises 11% ↗

August 07, 2025

Via The Motley Fool

Topics Intellectual Property

UROGEN PHARMA LTD (NASDAQ:URGN) Reports Mixed Q2 2025 Earnings Amid Widening Losses and Revenue Beat ↗

August 07, 2025

UroGen Pharma (URGN) reported Q2 2025 revenue of $24.2M, beating estimates, but EPS missed at -$1.05. JELMYTO sales grew 11% YoY, while ZUSDURI launch and R&D costs widened losses. Shares dipped...

Via Chartmill

3 Bullish Biotech Stocks With Explosive Growth Trends ↗

July 21, 2025

These small-cap biotech stocks offer high-reward potential with bullish momentum and key catalysts ahead in urology, autoimmune, and gene editing therapies

Via MarketBeat

Sage Therapeutics, Roku, EchoStar And Other Big Stocks Moving Higher On Monday ↗

June 16, 2025

Via Benzinga

US Stocks Likely To Rebound After Sharp Decline Amid Israel-Iran Conflict: S&P 500 Historically Moves Higher After Wars, Says Expert ↗

June 16, 2025

U.S. stock futures were trading higher on Monday following Friday's sharp declines. Futures of benchmark indices were higher in premarket.

Via Benzinga

Topics Stocks

UroGen Pharma Stock Scores Bullish Price Target Revisions Up To $47 Following FDA Nod For Zusduri ↗

June 16, 2025

UroGen Pharma shares rallied to a three-month high after the FDA approved Zusduri, a non-surgical treatment for a type of bladder cancer.

Via Stocktwits

Why UroGen Pharma (URGN) Stock Is Skyrocketing This Week ↗

June 13, 2025

UroGen Pharma shares are surging this week after the company gained FDA approval for ZUSDURI. The positive clinical trial results and an analyst upgrade fueled a significant stock price increase.

Via Benzinga

Top movers in Friday's session ↗

June 13, 2025

Looking for insights into the US markets in the middle of the day on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Via Chartmill

FDA Approves UroGen's Zusduri As First Drug For Recurrent Bladder Cancer ↗

June 13, 2025

FDA approves UroGen's Zusduri for recurrent low-grade bladder cancer, offering a non-surgical alternative with sustained response outcomes.

Via Benzinga

Unusual Machines, Celldex Therapeutics, RH And Other Big Stocks Moving Higher On Friday ↗

June 13, 2025

Via Benzinga

UroGen Soars On Price Target Upgrade On Heels Of FDA Approval For Cancer Medicine: Retail Sees Stock Touching $20 ↗

June 13, 2025

The new price target of $30 implies a near 171% upside to the stock’s closing price of $11.08 on Thursday.

Via Stocktwits

Here are the top movers in Thursday's session. ↗

June 12, 2025

Curious to know what's happening on the US markets one hour before the close of the markets on Thursday? Join us as we explore the top gainers and losers in today's session.

Via Chartmill

Which stocks are moving on Friday? ↗

June 06, 2025

Let's have a look at what is happening on the US markets one hour before the close of the markets on Friday. Below you can find the top gainers and losers in today's session.

Via Chartmill

UroGen Pharma Stock Receives Downgrade As Analyst Cites FDA Panel Setback For Key Bladder Cancer Drug ↗

May 25, 2025

Analyst Selvaraju downgrades UroGen after FDA panel setback dims approval prospects for key bladder cancer drug UGN-102.

Via Benzinga

This Guidewire Software Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday ↗

May 22, 2025

Via Benzinga

What's Going On With UroGen Pharma Stock Wednesday? ↗

May 21, 2025

UroGen shares traded lower Wednesday after the ODAC of the Food and Drug Administration voted against the benefit/risk of UGN-102 (mitomycin) for intravesical solution.

Via Benzinga

UroGen Stock Slumps After FDA Advisory Committee Flag Concerns On Its Investigational Drug: But Retail’s Unruffled ↗

May 21, 2025

The Food and Drug Administration is expected to conclude its review of UroGen’s UGN-102 application by June 13.

Via Stocktwits

Topics Artificial Intelligence

Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗

May 16, 2025

Here are the top movers in Friday's session, showcasing the stocks with significant price changes.

Via Chartmill

Top stock movements in today's session. ↗

May 16, 2025

Wondering how the US markets performed in the middle of the day on Friday? Discover the movers and shakers of today's session in our comprehensive analysis.

Via Chartmill

The market is filled with gapping stocks in Friday's session. ↗

May 16, 2025

Let's delve into the US markets on Friday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.

Via Chartmill

UroGen Pharma Touts Four-Year Response With Urothelial Cancer Drug Study, Highlights Potential For Bladder Cancer Candidates ↗

April 28, 2025

UroGen Pharma reports strong long-term data for Jelmyto and UGN-102 in cancer studies and shares promising early results for UGN-301 in bladder cancer.

Via Benzinga

Cemex Posts Q1 Results, Joins Plug Power, Sabre And Other Big Stocks Moving Higher On Monday ↗

April 28, 2025

Via Benzinga

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.